120 patents
Page 2 of 6
Utility
Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression
23 May 23
Oligonucleotides are provided herein that inhibit MARC1 expression.
Henryk Dudek, Wen Han, Natalie Wayne Pursell, Chengjung Lai, William Geoffrey Haynes, Zhihao Ding
Filed: 27 May 22
Utility
Extended dicer substrate agents and methods for the specific inhibition of gene expression
25 Apr 23
The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell.
Bob Dale Brown
Filed: 12 Nov 20
Utility
Methods and compositions for treating bile duct paucity-associated conditions
25 Apr 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing CTNNB1 expression, particularly in hepatocytes, for the treatment of bile duct paucity-associated conditions.
Natalie Pursell, Cheng Lai
Filed: 15 Feb 19
Utility
4'-O-METHYLENE Phosphonate Nucleic Acids and Analogues Thereof
20 Apr 23
Weimin WANG, Hongchuan YU
Filed: 15 Jan 21
Utility
Methods and Compositions for the Specific Inhibition of Kras by Asymmetric Double-stranded Rna
13 Apr 23
This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
Bob D. Brown
Filed: 25 Aug 22
Utility
Compositions and Methods for Inhibiting ALPHA-1 Antitrypsin Expression
6 Apr 23
This disclosure relates to compounds, compositions, and methods useful for reducing α-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob Dale BROWN, Natalie Wayne PURSELL, Chengjung LAI
Filed: 29 Oct 21
Utility
Compositions Comprising Reversibly Modified Oligonucleotides and Uses Thereof
30 Mar 23
Disclosed herein are glutathione-sensitive oligonucleotides and methods of using the same.
Weimin WANG, Venkata KRISHNAMURTHY
Filed: 9 Jun 22
Utility
Extended dicer substrate agents and methods for the specific inhibition of gene expression
7 Mar 23
The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell.
Bob Dale Brown
Filed: 8 Nov 21
Utility
4'-PHOSPHATE Analogs and Oligonucleotides Comprising the Same
2 Mar 23
Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4′-phosphate analog and methods of using the same, for example, to modulate the expression of a target gene in a cell.
Weimin WANG, Qingyi LI, Naim NAZEF
Filed: 7 Jul 22
Utility
Methods and Compositions for the Specific Inhibition of Transthyretin (TTR) by Double-stranded Rna
23 Feb 23
This invention relates to compounds, compositions, and methods useful for reducing transthyretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. BROWN, Henryk T. DUDEK
Filed: 1 Jul 21
Utility
Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expression
14 Feb 23
Oligonucleotides are provided herein that inhibit NR1H3 expression.
Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
Filed: 19 Apr 22
Utility
Compositions and Methods for Inhibiting Mitochondria Amidoxime Reducing Component 1 (MARC1) Expression
9 Feb 23
Oligonucleotides are provided herein that inhibit MARC1 expression.
Henryk Dudek, Wen Han, Natalie Wayne Pursell, Chengjung Lai, William Geoffrey Haynes, Zhihao Ding
Filed: 27 May 22
Utility
Reducing beta-catenin expression to potentiate immunotherapy
7 Feb 23
Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy.
Shanthi Ganesh, Marc Abrams
Filed: 28 Mar 18
Utility
Compositions and methods for inhibiting GYS2 expression
7 Feb 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes.
Bob D. Brown, Natalie Pursell, Henryk T. Dudek, Cheng Lai
Filed: 15 Feb 19
Utility
PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
31 Jan 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing PCSK9 expression, particularly in hepatocytes.
Henryk T. Dudek, Jihye Park
Filed: 1 Apr 19
Utility
Methods for Treating Hepatitis B Infection
5 Jan 23
This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
Martin KOSER, Marc ABRAMS
Filed: 2 Feb 22
Utility
Therapeutic Inhibition of Lactate Dehydrogenase and Agents Therefor
15 Dec 22
This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. BROWN, Henryk T. DUDEK, Cheng LAI
Filed: 13 May 22
Utility
Methods and Compositions for the Specific Inhibition of ALPHA-1 Antitrypsin by Double-stranded Rna
15 Dec 22
This invention relates to compounds, compositions, and methods useful for reducing α-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob Dale BROWN, Henryk T. DUDEK
Filed: 9 Jun 22
Utility
Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
22 Nov 22
Disclosed herein are methods for the treatment of cancer, comprising administering to a subject β-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule.
Marc Abrams, Shanthi Ganesh
Filed: 29 Sep 20
Utility
Compositions and Methods for Modulating PNPLA3 Expression
17 Nov 22
Oligonucleotides and compositions including the same are disclosed for inhibiting or reducing patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression.
Utsav SAXENA, Henryk T. DUDEK, Marc ABRAMS, Anton TURANOV, Bob Dale BROWN
Filed: 13 Apr 22